<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01644305</url>
  </required_header>
  <id_info>
    <org_study_id>3849</org_study_id>
    <nct_id>NCT01644305</nct_id>
  </id_info>
  <brief_title>Plasma Levels of GDF-9 and GDF-15 in Patients With Polycystic Ovary Syndrome.</brief_title>
  <official_title>1. Association of Plasma GDF-9 or GDF-15 Levels With Bone Parameters in Polycystic Ovary Syndrome. 2. Plasma GDF-15 Levels and Their Association With Hormonal and Metabolic Status in Women With Polycystic Ovary Syndrome Aged 25-35.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankara Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ankara Education and Research Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the plasma levels of GDF-9 and GDF-15, and their
      association with bone and cardiovascular parameters in patients with Polycystic Ovary
      Syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The association of GDF 9 AND GDF 15 with bone and cardiovascular parameters in women with polycystic ovary syndrome</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">85</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Polycystic Ovary Syndrome</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Idiopathic hirsutism</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital Endocrinology Outpatient Clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients at ages 25-35 diagnosed with polycystic ovarian syndrome and
             idiopathic hirsutism

        Exclusion Criteria:

          -  acute infectious disease, a thyroid, pituitary, nutritional, inflammatory, hepatic,
             renal, or neoplastic disorder; history of cardiovascular disease or pulmonary
             embolism; a family history of coronary artery disease; smoking history; hypertension;
             diabetes mellitus; use of oral contraceptives, anti-androgens and drugs known to
             interfere with cytokine release, such as corticosteroids, immunosuppressors, or
             nonsteroidal antiinflammatory drugs.

        any medication known to affect hormonal or metabolic parameters.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Ankara Education and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 17, 2012</study_first_submitted>
  <study_first_submitted_qc>July 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2012</study_first_posted>
  <last_update_submitted>June 26, 2018</last_update_submitted>
  <last_update_submitted_qc>June 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ankara Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Zehra Berberoglu</investigator_full_name>
    <investigator_title>Ass. Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

